➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Johnson and Johnson
Moodys
McKinsey
Merck

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,289,586

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,289,586 protect, and when does it expire?

Patent 9,289,586 protects AXIRON and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 9,289,586
Title:Spreading implement
Abstract: An implement for applying a volume of liquid to a treatment surface includes a support onto which is mounted a receptacle. The receptacle defines a reservoir space which receives the liquid. The receptacle includes a wall having a working surface that is used to spread the liquid over the treatment surface. The wall is resiliently deformable such that in use the working surface maintains contact with the treatment surface when spreading the liquid. The implement is used in applying a transdermal lotion to the axilla area of a user. A system for transdermal administration of a physiological active agent from a liquid composition and a method of conducting the same are also provided.
Inventor(s): Bayly; Peter (Victoria, AU), Bayly; Mark Simon (Victoria, AU), Ahlstrom; Magnus (Victoria, AU), Watkinson; Adam Charles (Somerset, GB)
Assignee: ACRUX DDS PTY LTD (Victoria, AU)
Application Number:14/317,412
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,289,586
Patent Claim Types:
see list of patent claims
Use; Composition; Device;

Drugs Protected by US Patent 9,289,586

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No   Start Trial   Start Trial A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,289,586

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007343579   Start Trial
Brazil PI0720945   Start Trial
Canada 2674661   Start Trial
China 101636194   Start Trial
Eurasian Patent Organization 015473   Start Trial
Eurasian Patent Organization 200900987   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
AstraZeneca
Harvard Business School
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.